Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy

Labcorp is now the only lab that can detect preeclampsia risk across all pregnancy trimesters BURLINGTON, N.C. , May 15, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia

Overcoming key challenges in global cell and gene therapy trials with Labcorp

Cell and gene therapies (CGT) represent the future of precision medicine, offering the potential to improve patient outcomes across a range of diseases. However, bringing these complex therapies from bench to bedside presents unique challenges at every stage of development. As the CGT landscape continues to evolve rapidly, developers need an experienced partner who can provide integrated solutions to overcome key hurdles at every stage from early research through commercialization. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Franklin, PhD, vice president and enterprise head of CGT at Labcorp, shared how Labcorp’s comprehensive CGT capabilities support all aspects of global CGT development, including preclinical pharmacology, companion diagnostics (CDx) development and validation.

The three pillars for good employee mental health

May is Mental Health Awareness Month and a great time to look at a new, positive and proactive approach to mental health with your employees. Like measures taken to prevent and treat medical conditions such as heart disease and diabetes, according to recent evidence, lifestyle and behavioral changes similarly can be implemented to improve mental wellness. 

Labcorp to Webcast Its Annual Meeting of Shareholders

BURLINGTON, N.C. , May 8, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 14 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations

Invitae Receives Court Approval for Sale to Labcorp

Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases Key milestone reached in Invitae's Chapter 11 process BURLINGTON, N.C. and SAN FRANCISCO , May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive

Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer

OX40/OX40 Ligand and its Role in Precision Immune Oncology

Breathing new life into inhaled medicines

Taking an inhaled medication can be as easy as taking a breath. This simple and painless drug-delivery method has always been a preferred option for respiratory drugs. The inhaled medicine market is booming. There are more than 100 pharmaceutical compounds in development for the treatment of respiratory ailments, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). It is also quickly becoming the method of choice for a variety of more diverse and systemic therapies as an alternative to needle injections or other invasive applications, which are less desirable to patients—such as for Parkinson’s disease, seizures, diabetes and analgesics.